pyrroles has been researched along with Atheroma in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 85 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CW; Park, SJ | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Delgado, G; Naves, M | 1 |
| Bremer, C; Demmer, P; Frenzel, T; Hahnenkamp, A; Immenschuh, S; Larmann, J; Schmitz, M; Theilmeier, G; Tietge, UJ | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Guo, RW; Heng, XH; Qi, F; Si, YK; Yang, LX; Zhou, XB | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G | 1 |
| Gao, J; Gao, X; Pan, S | 1 |
| King, A | 1 |
| Abdelbaky, A; Alon, A; Beals, CR; Dansky, H; Farkouh, ME; Fayad, ZA; Klimas, MT; Mogg, R; Nunes, IO; Rudd, JH; Shankar, SS; Subramanian, SS; Tawakol, A | 1 |
| Gerber, BL | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| de Graaf, MA; Jukema, JW | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Davoodpour, P; Larsson, L; Malm, J; Mörk, LM; Norata, GD; Parini, P; Rehnmark, S; Witt, MR | 1 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Fang, D; Jia, H; Qu, Z; Quan, W; Quan, Z; Yang, S | 1 |
| Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Kawahara, T; Suzuki, G | 1 |
| Koh, KK | 2 |
| Emami, H; Farkouh, M; Fayad, ZA; Fifer, K; Rudd, JH; Subramanian, S; Tawakol, A; Van Dyke, T | 1 |
| Cai, Z; He, B; Hu, L; Jin, S; Li, D; Nie, P; Shao, Q; Shen, J; Shen, L; Xiao, H; Yi, J; Yu, Y | 1 |
| Gamou, T; Hayashi, K; Higashikata, T; Hirase, H; Ino, H; Kanaya, H; Katsuda, S; Kawashiri, MA; Konno, T; Michishita, I; Miwa, K; Mizuno, S; Nagase, K; Namura, M; Nitta, Y; Okeie, K; Sakata, K; Tada, H; Terashima, M; Uchiyama, K; Ueda, K; Yamagishi, M | 1 |
| Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Ashrafi, A | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Asrar Ul Haq, M; Mutha, V; Rudd, N; Subiakto, I; Van Gaal, WJ | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katsimpoulas, M; Kostakis, A; Kostomitsopoulos, N; Liapis, CD; Moustardas, P | 1 |
| Ai, R; Chen, F; Li, G; Lu, WH; Tang, ZZ; Wu, XW | 1 |
| Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C | 1 |
| Moreno, PR | 1 |
| Akagi, H; Akasaka, T; Imanishi, T; Ino, Y; Kitabata, H; Komukai, K; Kubo, T; Kumiko, H; Matsuo, Y; Okumoto, Y; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Takarada, S; Tanaka, A; Tanimoto, T; Ueno, S; Yamaguchi, T; Yamano, T | 1 |
| Chen, M; Huang, BT | 1 |
| Nicholls, SJ; Puri, R; Shao, M; Stegman, B | 1 |
| Abdelbaky, A; Ballantyne, CM; Du, S; Ehlgen, A; Emami, H; Farkouh, ME; Farmer, M; Fayad, ZA; Hayes, W; Kim, J; Langenickel, TH; Li, L; Mohler, ER; Roth, E; Subramanian, S; Tawakol, A; Velasquez, L; Vucic, E | 1 |
| Crea, F; Niccoli, G | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Hokimoto, S; Kaikita, K; Ogawa, H; Shimomura, H; Sugiyama, S; Tsujita, K; Yamanaga, K | 4 |
| Goldstein, MR; Mascitelli, L | 1 |
| Lloyd-Jones, D; Smith, S; Stone, NJ | 1 |
| Chapman, J; Giral, P; Hansel, B | 1 |
| Bedogni, F; Montone, RA; Testa, L | 1 |
| Abdel-Wahab, M; Richardt, G | 1 |
| Goldwasser, F; Mir, O; Ropert, S; Vignaux, O | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G | 1 |
| Andersson, KE; Eussen, SR; Garssen, J; Hellstrand, P; Klungel, OH; Oste, R; Rompelberg, CJ; van Kranen, H | 1 |
| Ascaso, JF; Lorente, R; Martínez-Hervás, S; Molina, M; Navarro-Hidalgo, MI; Priego, A; Real, JT | 1 |
| Andrys, C; Brcakova, E; Micuda, S; Mullerova, Z; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Kawaguchi, R | 1 |
| Saito, Y | 1 |
| Chapman, MJ | 1 |
| Takagi, H; Umemoto, T | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Miyauchi, K | 1 |
| Hasebe, N; Ota, H; Takeuchi, T | 1 |
| Chan, CW; Chan, KK; Chan, PH; Chan, RH; Hau, WK; Kong, SL; Lam, SC; Lam, YM; Lee, SW; Tam, FC; Tse, HF; Wong, MK | 1 |
| Brown, K; Bucerius, J; Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Kotsuma, M; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Ramachandran, S; Roytman, M; Rudd, JH; Tanimoto, T; Tsimikas, S; Vucic, E | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S | 1 |
| Fujii, K; Masuyama, T | 1 |
| Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Guo, R; Heng, X; Liang, X; Shi, Y; Yang, L; Zhou, X | 1 |
6 review(s) available for pyrroles and Atheroma
| Article | Year |
|---|---|
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Plaque, Atherosclerotic; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis | 2012 |
The role of endoglin in atherosclerosis.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
23 trial(s) available for pyrroles and Atheroma
| Article | Year |
|---|---|
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Treatment Outcome | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
[Series: Clinical study from Japan and its reflections; atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Aorta; Atorvastatin; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk | 2014 |
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug Combinations; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2015 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarc
Topics: Anti-Arrhythmia Agents; Atorvastatin; Benzazepines; Biomarkers; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Emergencies; Femoral Neck Fractures; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Middle Aged; Myocardial Infarction; Orthopedic Procedures; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Research Design; Risk Factors; Severity of Illness Index; Tachycardia, Ventricular; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2014 |
The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diet, High-Fat; Elastin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Physical Conditioning, Animal; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2014 |
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography | 2015 |
Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Tomography, Optical Coherence | 2014 |
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multimodal Imaging; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazines; United States | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors | 2012 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
58 other study(ies) available for pyrroles and Atheroma
| Article | Year |
|---|---|
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography | 2014 |
In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Arteries; Atorvastatin; Cell Migration Assays, Macrophage; Cells, Cultured; Diet; Fluorescence; Green Fluorescent Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Tomography | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arachidonate 5-Lipoxygenase; Atherosclerosis; Atorvastatin; Chemokine CCL3; Cholesterol, Dietary; Down-Regulation; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotrienes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Signal Transduction | 2013 |
Effect of minocycline on carotid atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Minocycline; Plaque, Atherosclerotic; Pyrroles; Rabbits | 2013 |
Vascular disease: aortic plaque--dual therapy for a heterogeneous disease.
Topics: Aortic Diseases; Calcinosis; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Plaque, Atherosclerotic; Pyrroles | 2013 |
In vivo evaluation of atherosclerotic plaque inflammation and of anti-inflammatory effects of statins by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima | 2013 |
The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cytokines; Disease Models, Animal; Drug Synergism; Feces; Heptanoic Acids; Male; Mice; Mice, Knockout; Molecular Mimicry; Plaque, Atherosclerotic; Pyrroles; Thyroid Hormones | 2013 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Atorvastatin; Diet, High-Fat; Gene Expression Regulation; Heptanoic Acids; NF-kappa B; Plaque, Atherosclerotic; Pyrroles; Rabbits; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2014 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?
Topics: Aorta, Thoracic; Atherosclerosis; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2014 |
Reply: is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?
Topics: Aorta, Thoracic; Atherosclerosis; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2014 |
Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors.
Topics: Animals; Apolipoproteins E; Atorvastatin; Chemokines; Collagenases; Heptanoic Acids; Macrophages; Mice; Mice, Knockout; Monocytes; Plaque, Atherosclerotic; Pyrroles; Receptors, Chemokine; Time Factors | 2014 |
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction | 2014 |
Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Plaque, Atherosclerotic; Porphyromonas gingivalis; Pyrroles; Rabbits; Vascular Cell Adhesion Molecule-1 | 2014 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; gamma-Glutamyltransferase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Strengthening the Achilles heel of high-risk plaques.
Topics: Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Tomography, Optical Coherence | 2014 |
Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Infarction; Intestines; Male; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Sunitinib; Thromboembolism; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2011 |
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome | 2011 |
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Avena; beta-Glucans; Blood; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fiber; Eating; Female; Heptanoic Acids; Intestinal Absorption; Lipids; Liver; Mice; Mice, Inbred Strains; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2011 |
[Subclinical carotid atherosclerosis in patients with familial combined hyperlipidemia. Two years follow-up after treatment with high doses of atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Statistics, Nonparametric; Ultrasonography | 2012 |
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers, Pharmacological; Blood; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Endoglin; Female; Heptanoic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Sinus of Valsalva; Smad1 Protein; Vascular Endothelial Growth Factor A | 2011 |
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin.
Topics: Animals; Apolipoproteins B; Atorvastatin; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver X Receptors; Macrophages; Multimodal Imaging; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Rabbits; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color | 2012 |
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study.
Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum | 2013 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |